Radioiodine-refractory thyroid cancers treated with Lenvatinib：A report of five cases

DOI
  • HIGUCHI Ryota
    Department of Otorhinolaryngology Head and Neck, Graduate School of Medical Sciences, Kyushu University
  • NAKANO Takafumi
    Department of Otorhinolaryngology Head and Neck, Graduate School of Medical Sciences, Kyushu University
  • ARITA Shuji
    Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University
  • KUSABA Hitoshi
    Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University
  • KOGO Ryunosuke
    Department of Otorhinolaryngology Head and Neck, Graduate School of Medical Sciences, Kyushu University
  • URYU Hideoki
    Department of Otorhinolaryngology Head and Neck, Graduate School of Medical Sciences, Kyushu University
  • YASUMATSU Ryuji
    Department of Otorhinolaryngology Head and Neck, Graduate School of Medical Sciences, Kyushu University
  • NAKASHIMA Torahiko
    Department of Otorhinolaryngology Head and Neck, Graduate School of Medical Sciences, Kyushu University
  • NAKAGAWA Takashi
    Department of Otorhinolaryngology Head and Neck, Graduate School of Medical Sciences, Kyushu University

Bibliographic Information

Other Title
  • 根治切除不能な甲状腺癌に対するレンバチニブの使用経験

Search this article

Description

<p>Patients with thyroid cancer are normally treated with surgery, while patients with advanced cancer are usually treated with radioactive iodine. However, there is no effective treatment for patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). As a result, such patients are generally treated with radiotherapy or chemotherapy. Lenvatinib has been approved in Japan for the treatment of RR-DTC since May 2015, and is a potent oral Tyrosine kinase inhibitor (TKI) of different growth factor receptors, including VEGFR and FGFR. However,this molecular target drug has been reported to be associated with some side effects. We herein report 5 cases that were treated with lenvatinib, including 3 cases of papillary carcinoma, 1 case of squamous cell carcinoma, and 1 case of papillary carcinoma with squamous cell carcinoma. The main side effects were hypertension, fatigue, loss of appetite, and stomatitis. This drug was effective for 2 of 3 patients with papillary carcinoma, and this proportion is roughly in agreement with the findings of previous studies. Patients with squamous cell carcinoma (SCC) tend to show progressive disease. On the other hand, lenvatinib has been shown to be effective for only primary lesion in one of patients with SCC, but not for metastatic lesions. There has so far been no report of patients with squamous cell carcinoma of thyroid cancer that were successfully treated with lenvatinib, and therefore further studies are needed.</p>

Journal

  • jibi to rinsho

    jibi to rinsho 63 (2), 47-54, 2017-03-20

    JIBI TO RINSHO KAI

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top